HMA/EMA multi-stakeholder workshop on artificial intelligence (AI) - enabling the safe and responsible use of AI, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 5 November 2024, 09:00 (CET) to 5 November 2024, 17:40 (CET)

Table of decisions of labelling exemption requests falling under article 63 of Directive 2001/83/EC examined by the Quality Review of Documents (QRD) Group

Minutes of the PRAC meeting 28-31 October 2024

Financial advantages of SME status

Timetable: Initial (full) marketing authorisation application accelerated assessment timetables - Advanced therapy medicinal product (ATMP)

Timetable: Extension application - ATMP

Human medicines European public assessment report (EPAR): Pheburane, sodium phenylbutyrate, Date of authorisation: 30/07/2013, Revision: 13, Status: Authorised

Work plan for the Committee for Veterinary Medicinal Products (CVMP) Pharmacovigilance Working Party (PhVWP-V) 2025

Policy 44: European Medicines Agency policy on the handling of competing interests of scientific committees’ members and experts - As adopted by EMA Management Board on 11-12 December 2024

Policy 58: European Medicines Agency policy on the handling of competing interests of Management Board members - As adopted by EMA Management Board on 11-12 December 2024